A novel preclinical mouse model of pancreatic cancer may promote better understanding of the mechanisms that lead to disability in human cancer patients, according to the findings of a new study presented this week at the Association of Academic Physiatrists Annual Meeting.
Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients. The study, which will be published May 22 in the Journal of Experimental Medicine, suggests that targeting this pathway with a drug already in phase 2 clinical trials for diabetes could prevent this syndrome.
Research in mice suggests that supplementing the essential nutrient methionine combined with radiation therapy impairs gut function to promote a life-threatening form of radiation toxicity. The study highlights the importance of food and nutrition professionals as part of a cancer treatment team.